They also provide a detailed picture of the various co-stimulatory molecules and immune checkpoints expressed by tumor-infiltrating CD4+ T cells and demonstrate the promise of new combined cancer immunotherapies to be explored in NSCLC patients. This evidence concerns the gene CD4 and cancer.